What vaccines are recommended for adults, including recommended schedules and indications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Adult Vaccination Recommendations

All adults should receive annual influenza vaccination, a one-time Tdap dose followed by Td boosters every 10 years, and age-appropriate pneumococcal, zoster, and other vaccines based on specific risk factors and age groups. 1, 2

Universal Vaccines for All Adults

Influenza Vaccination

  • Annual vaccination required for all adults ≥19 years with inactivated (IIV), recombinant (RIV), or live attenuated (LAIV) formulations 1, 2
  • Trivalent formulations are now standard (updated from quadrivalent) 1
  • LAIV contraindicated in pregnancy and immunocompromised patients 3

Tetanus, Diphtheria, Pertussis (Tdap/Td)

  • One-time Tdap dose for all adults who haven't received it, then Td or Tdap booster every 10 years 3, 1
  • Pregnant women: Tdap during EACH pregnancy, preferably weeks 27-36 3
  • Critical pitfall: Many providers forget the pregnancy dose—this protects newborns through passive immunity

Age-Based Vaccination Schedule

Ages 19-26 Years

  • HPV vaccine: 2-3 doses depending on age at initiation (catch-up through age 26) 3, 1
  • MMR: 1-2 doses if born in 1957 or later without evidence of immunity 3
  • Varicella: 2 doses if born in 1980 or later without evidence of immunity 3

Ages 27-49 Years

  • HPV: May be offered ages 27-45 based on shared clinical decision-making 4, 1
  • Continue routine Td/Tdap and annual influenza

Ages 50-64 Years

  • Zoster (shingles): 2-dose series of RZV (recombinant, preferred) starting at age 50 3, 1
    • RZV given 2-6 months apart (minimum 4 weeks) 3
    • ZVL (live vaccine) is alternative but less preferred 3

Ages ≥65 Years

  • Pneumococcal vaccination—this has evolved significantly:

    • 2024-2025 guidance: PCV13 no longer routinely recommended for all adults ≥65 4, 1
    • PPSV23: One dose universally recommended at age ≥65 4
    • PCV13: Based on shared clinical decision-making for immunocompetent adults ≥65 4
    • Higher-risk groups (nursing home residents, chronic conditions, smokers) may benefit more from PCV13 4
  • RSV vaccine: New recommendation for adults ≥75 years (universal); ages 60-74 with risk factors 1, 2

Risk-Based Vaccinations

Immunocompromised Patients (HIV, transplant, immunosuppressive therapy, asplenia)

Critical timing: Vaccinate at least 2 weeks before planned immunosuppression; avoid during active chemotherapy/radiation 5

  • Pneumococcal: PCV13 followed by PPSV23 at least 8 weeks later 5, 3

    • If already received PPSV23: Give PCV13 ≥1 year after last PPSV23 5
    • Additional PPSV23 doses: ≥8 weeks after PCV13 and ≥5 years after prior PPSV23 5
  • Meningococcal: 2 doses MCV4 at least 2 months apart for asplenia or complement deficiencies 5

  • HIV patients: Vaccinate as soon as possible after diagnosis 5

  • Live vaccines (MMR, varicella, ZVL, LAIV): CONTRAINDICATED 3

Chronic Medical Conditions

Ages 19-64 with chronic heart/lung disease, diabetes, chronic liver disease, alcoholism, or smoking:

  • PPSV23: One dose 3
  • Annual influenza (IIV/RIV only, not LAIV for some conditions) 3

Hepatitis Vaccination

Hepatitis A (2-3 doses depending on vaccine): 3

  • Chronic liver disease
  • Clotting factor disorders
  • Men who have sex with men
  • Injection drug users
  • Travel to endemic areas

Hepatitis B (2-3 doses depending on vaccine): 3, 6

  • All diabetics ≤60 years 7
  • End-stage renal disease/hemodialysis (special high-dose formulation: 40 µg/mL or double 20 µg/mL dose) 6
  • HIV infection
  • Chronic liver disease
  • Men who have sex with men
  • Injection drug users
  • Healthcare personnel
  • Note: Heplisav-B contraindicated in pregnancy (no safety data) 3

Meningococcal Vaccination

MenACWY (1-2 doses, boosters every 5 years if risk persists): 5, 3

  • Asplenia or complement deficiencies (2 doses, 2 months apart)
  • HIV infection (2 doses)
  • Microbiologists exposed to N. meningitidis
  • Travel to hyperendemic areas
  • First-year college students in dorms through age 21 (if not vaccinated after age 16)

MenB (2-3 doses depending on vaccine): 1, 2

  • Ages 16-23 (preferred 16-18) based on shared clinical decision-making
  • Asplenia, complement deficiencies (required, not optional)

Healthcare Personnel

  • Annual influenza 3
  • Tdap (if not previously received) 3
  • MMR: 2-dose series if born in 1957 or later 3
  • Varicella: 2 doses if no evidence of immunity 3
  • Hepatitis B: 3-dose series 6

Critical Timing Considerations

Elective splenectomy: Vaccinate ≥2 weeks before surgery 5, 6

Immunosuppressive therapy: Vaccinate ≥2 weeks before initiation 5

PPSV23 revaccination:

  • One-time revaccination 5 years after first dose for ages 19-64 with renal failure, asplenia, or immunocompromising conditions 5
  • If received PPSV23 before age 65: Give another dose at ≥65 if ≥5 years since last dose 5
  • No further doses needed if vaccinated at/after age 65 5

Common Pitfalls to Avoid

  1. Forgetting Tdap in every pregnancy—this is the single most missed vaccine in practice
  2. Not checking vaccination status in immunocompromised patients before starting therapy—once on chemotherapy, it's too late for many vaccines
  3. Assuming older adults are "caught up"—many need MMR, varicella if born after certain years
  4. Missing the PCV13/PPSV23 sequencing—order matters for immunocompromised patients
  5. Not offering HPV vaccine to adults through age 26—catch-up is still beneficial
  6. Giving live vaccines to immunocompromised patients—can cause severe disease

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.